tbuckley/cabot-search huggingface dataset:
The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy
Authors: David J Park, Min Thura, Vi K Chiu, Brian Vicuna, Koon Hwee Ang, Blanca Sanchez, Pei Ling Chia, Kam Yew Kuan, Jie Li, Ke Zhang, Wei Hui Zheng, Matthew Chau Hsien Ng, Qi Zeng
Journal: Cell Reports Medicine (2025)
Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial
Authors: Cihan Gani, Emmanouil Fokas, Bülent Polat, Oliver J Ott, Markus Diefenhardt, Alfred Königsrainer, Simon Böke, Andreas Kirschniak, Robert Bachmann, Dörte Wichmann, Michael Bitzer, Stephan Clasen, Ulrich Grosse, Rüdiger Hoffmann, Martin Götz, Ralf-Dieter Hofheinz, Elisabeth Germer, Christoph-Thomas Germer, Rainer Fietkau, Peter Martus, Daniel Zips, Claus Rödel
Journal: The Lancet. Gastroenterology & hepatology (2025)
Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001
Authors: Vanessa Blumer, James L Januzzi, Yuxi Liu, Javed Butler, Justin A Ezekowitz, Riccardo Perfetti, Julio Rosenstock, Stefano Del Prato, W H Wilson Tang, Alessia Urbinati, Faiez Zannad, Gregory D Lewis, Scott D Solomon, Sheila Hedge, Nasrien E Ibrahim, Carolyn S P Lam
Journal: JACC Heart Failure (2025)
Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial
Authors: Anthony Yuen Bun Teoh, Sundeep Lakhtakia, Ilaria Tarantino, Manuel Perez-Miranda, Rastislav Kunda, Fauze Maluf-Filho, Vinay Dhir, Jahangeer Basha, Shannon Melissa Chan, Dario Ligresti, Mark Tsz Wah Ma, Carlos de la Serna-Higuera, Hon Chi Yip, Enders Kwok Wai Ng, Philip Wai Yan Chiu, Takao Itoi
Journal: The Lancet. Gastroenterology & hepatology (2025)
Plasmalogen remodeling modulates macrophage response to cytotoxic oxysterols and atherosclerotic plaque vulnerability
Authors: Antoine Jalil, Thomas Pilot, Thibaut Bourgeois, Aline Laubriet, Xiaoxu Li, Marc Diedisheim, Valérie Deckert, Charlène Magnani, Naig Le Guern, Jean-Paul Pais de Barros, Maxime Nguyen, Gaëtan Pallot, Adrien Vouilloz, Lil Proukhnitzky, François Hermetet, Virginie Aires, Eric Lesniewska, Laurent Lagrost, Johan Auwerx, Wilfried Le Goff, Nicolas Venteclef, Eric Steinmetz, Charles Thomas, David Masson
Journal: Cell Reports Medicine (2025)
Dysfunctional one-carbon metabolism identifies vitamins B6, B9, B12, and choline as neuroprotective in glaucoma
Authors: James R Tribble, Vickie H Y Wong, Kelsey V Stuart, Glyn Chidlow, Alan Nicol, Anne Rombaut, Alessandro Rabiolo, Anh Hoang, Pei Ying Lee, Carola Rutigliani, Tim J Enz, Alessio Canovai, Emma Lardner, Gustav Stålhammar, Christine T O Nguyen, David F Garway-Heath, Robert J Casson, Anthony P Khawaja, Bang V Bui, Pete A Williams
Journal: Cell Reports Medicine (2025)
Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial
Authors: Guanlin Li, Vincent Wai-Sun Wong, Ruth Suk-Mei Chan, Daisy Man-Ching Sin, Winnie Chu, Vivian Wong, Catherine Cheung, Shirley Lam, Huapeng Lin, Suey Yeung, Timothy Chun-Man Li, Tracy Hang-Yee Ho, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip, Grace Chung-Yan Lui
Journal: The Lancet HIV (2025)
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread
Authors: Hannah Garner, Moreno Martinovic, Ning Qing Liu, Noor A M Bakker, Irene Querol Velilla, Cheei-Sing Hau, Kim Vrijland, Daphne Kaldenbach, Marleen Kok, Elzo de Wit, Karin E de Visser
Journal: Cancer Cell (2025)
CT-colonography in Fecal Immunochemical Test Positives in a Colorectal Cancer Screening Program
Authors: Sarah Moen, Fleur E Marijnissen, Jochim S Terhaar Sive Droste, Wouter H de Vos Tot Nederveen Cappel, B W Marcel Spanier, Jelle F Huisman, Evelien Dekker, Jaap Stoker, Ernst J Kuipers, Maarten G J Thomeer, Manon C W Spaander, Leonieke M M Wolters, Ivonne Leeuwenburgh, Merel M Tielemans, Xander G Vos, Mariette C A van Kouwen, Marjon Kerkhof, Ruud W M Schrauwen, Renzo P Veenstra, Lisette G Capelle, Marloes Bigirwamungu-Bargeman, Caroline A Wientjes, Conny van Enckevort, Sanna A Mulder, Djuna L Cahen, Tom C Seerden, Lennard P L Gilissen, Robbert Eichhorn, Paul Bus, Rogier J J de Ridder, Erik H C J Buster, Annick B van Nunen
Journal: Clinical Gastroenterology and Hepatology (2025)
The foam cell-derived exosomes exacerbate ischemic white matter injury via transmitting metabolic defects to microglia
Authors: Hang Zhang, Luo-Qi Zhou, Sheng Yang, Ming-Hao Dong, Lian Chen, Yi-Lin Lu, Lu-Yang Zhang, Lan Zhang, Yun-Hui Chu, Lu-Lu Xu, Xiao-Wei Pang, Li-Fang Zhu, Ting Xu, Tu-Ying Yong, Wei Wang, Dai-Shi Tian, Chuan Qin
Journal: Cell Metabolism (2025)
Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma
Authors: Shanshan Zhang, Yan Zhou, Zhonghua Liu, Yuqian Wang, Xiang Zhou, Haiwen Chen, Xinyu Zhang, Yanhong Chen, Qisheng Feng, Xiaoping Ye, Shanghang Xie, Mu-Sheng Zeng, Weiwei Zhai, Yi-Xin Zeng, Sumei Cao, Guideng Li, Miao Xu
Journal: Cancer Cell (2025)
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception
Authors: Bo Zhu, Pingjun Chen, Muhammad Aminu, Jian-Rong Li, Junya Fujimoto, Yanhua Tian, Lingzhi Hong, Hong Chen, Xin Hu, Chenyang Li, Natalie Vokes, Andre L Moreira, Don L Gibbons, Luisa M Solis Soto, Edwin Roger Parra Cuentas, Ou Shi, Songhui Diao, Jie Ye, Frank R Rojas, Eduardo Vilar, Anirban Maitra, Ken Chen, Nicolas Navin, Monique Nilsson, Beibei Huang, Simon Heeke, Jianhua Zhang, Cara L Haymaker, Vamsidhar Velcheti, Daniel H Sterman, Veena Kochat, William I Padron, Ludmil B Alexandrov, Zhubo Wei, Xiuning Le, Linghua Wang, Junya Fukuoka, J Jack Lee, Ignacio I Wistuba, Harvey I Pass, Mark Davis, Samir Hannash, Chao Cheng, Steven Dubinett, Avrum Spira, Kunal Rai, Scott M Lippman, P Andrew Futreal, John V Heymach, Alexandre Reuben, Jia Wu, Jianjun Zhang
Journal: Cancer Cell (2025)
Template-assisted sequence knock-in rescues skeletal and cardiac muscle function in a deletion model of Duchenne muscular dystrophy
Authors: Sina Fatehi, Matthew J Rok, Ryan M Marks, Emily Huynh, Natalie Kozman, Hong Anh Truong, Lijun Chi, Bei Yan, Enzhe Khazeeva, Paul Delgado-Olguin, Evgueni A Ivakine, Ronald D Cohn
Journal: Molecular Therapy (2025)
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study
Authors: Eva Blondeaux, Amir Sonnenblick, Elisa Agostinetto, Raphaëlle Bas, Hee J Kim, Maria A Franzoi, Rinat Bernstein-Molho, Sabine Linn, Ava Kwong, Katarzyna Pogoda, Judith Balmana, Ann Smeets, Jyoti Bajpai, Halle C F Moore, Ann H Partridge, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Fedro A Peccatori, Tiphaine Renaud, Alberta Ferrari, Shani Paluch-Shimon, Pablo Mando, Jeong E Lee, Robert Fruscio, Wanda Cui, Stephanie M Wong, Claudio Vernieri, Kathryn J Ruddy, Maria V Dieci, Alexios Matikas, Mariya Rozenblit, Deniz C Guven, Minna Lee, Cynthia Villarreal-Garza, Shelley E Hwang, Laura De Marchis, Fabio Puglisi, Zoe Kemp, Pedro A Meireles, Anastasia Parokonnaya, Gustavo Werutsky, Maiko Okano, Hatem A Azim, Kleida Mati, Shoshana Rosenberg, Richard Gelber, Luca Boni, Matteo Lambertini
Journal: The Lancet Oncology (2025)
Intrinsic/proximal cell surface marker logic-gated extracellular targeted protein degradation in specific cell population
Authors: Yafeng Wang, Guiquan Zhang, Ping Rong, Panpan Guo, Shisheng Huang, Yang Hang, Pei Wang, Lin Tang, Xiaojing Li, Xiaojun Tang, Shuai Ding, Xingxu Huang, Jianghuai Liu, Lingyun Sun
Journal: Molecular Therapy (2025)
FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease Type 1
Authors: Fabrizio Comper, Carlos J Miranda, Benjamin Liou, Tihomir Dodev, Jey M Jeyakumar, Miriam Canavese, Clement Cocita, Khashayar Khoshrou, Gustavo Tiscornia, Elisa Chisari, Emmaline Stotter, Erald Shehu, Sudharsan Sridharan, I-Mei Yu, Jalpa Pandya, Jaminder Khinder, Natalie Northcott, Petya Kalcheva, Samantha Correia, Ying Sun, Allison Dane, Rose Sheridan, Amit C Nathwani, Romuald Corbau
Journal: Molecular Therapy (2025)

Gaucher disease Type 1 (GD1) is caused by mutations in the GBA1 gene, which result in deficient enzyme β-glucocerebrosidase (GCase) activity and production with the harmful accumulation of the lipid substrate glucocerebroside. Replacement of GCase is current standard-of-care for GD1; however, GCase has a relatively short active half-life at both physiological and lysosomal pH and biweekly intravenous administration does not provide a consistent exposure to active enzyme. FLT201 is the first AAV gene therapy in clinical trials for treatment of GD1. FLT201 consists of a rationally designed AAV capsid (AAVS3) containing an expression cassette with an engineered GBA1 transgene that encodes a unique glucocerebrosidase variant (GCase85). GCase-85 includes an engineered disulfide, which results in a >6-fold increase in active half-life in human serum and a >21-fold increase in active half-life at lysosomal pH conditions, with similar catalytic properties to those of wild-type and exogenous GCase. Preclinical data indicates that FLT201 could offer a durable treatment for Gaucher disease Type 1, addressing unmet needs related to substrate accumulation in tissues poorly treated by current enzyme replacement therapy. The improved stability of the engineered GCase85 variant is predicted to be crucial for FLT201's therapeutic effectiveness.
The paraventricular thalamus mediates visceral pain and anxiety-like behaviors via two distinct pathways
Authors: Di Li, Yong-Chang Li, Zheng-Yan Zhu, Fu-Chao Zhang, Qiu-Ying Zhao, Jia-Hui Jiang, Biyu Shen, Yong Tang, Guang-Yin Xu
Journal: Neuron (2025)

Chronic visceral pain (CVP) often accompanies emotional disorders. However, the lack of suitable animal models has hindered research into their underlying molecular and neural circuitry mechanisms. Early-life stress is a key factor in developing both visceral hypersensitivity and emotional disorders, yet its pathological mechanisms are not well understood. This study showed that adult offspring of prenatal maternal stress (PMS)-exposed mice exhibited visceral hypersensitivity and anxiety-like behaviors. Glutamatergic neurons in the anterior paraventricular thalamus (aPVT) responded to visceral pain, while those in the posterior PVT (pPVT) were more responsive to anxiety. The aPVT-basolateral amygdala (BLA) and pPVT-central amygdala (CeA) circuits regulated CVP and anxiety, respectively. Notably, increased Cacna1e expression in aPVT enhanced both visceral pain and anxiety, while Grin2a upregulation in pPVT facilitated only anxiety. These findings highlight the distinct roles of aPVTGlu-BLAGlu-CeAGABA and pPVTGlu-CeAGABA circuits, providing insights for therapeutic approaches in CVP and anxiety comorbidity.
Selectively vulnerable deep cortical layer 5/6 fast-spiking interneurons in Alzheimer’s disease models in vivo
Authors: Amalia Papanikolaou, David Graykowski, Byung Il Lee, Mengke Yang, Robert Ellingford, Jana Zünkler, Suraya A Bond, James M Rowland, Rikesh M Rajani, Samuel S Harris, David J Sharp, Marc Aurel Busche
Journal: Neuron (2025)

Alzheimer's disease (AD) is initiated by amyloid-beta (Aβ) accumulation in the neocortex; however, the cortical layers and neuronal cell types first susceptible to Aβ remain unknown. Using in vivo two-photon Ca2+ imaging in the visual cortex of AD mouse models, we found that cortical layer 5 neurons displayed abnormally prolonged Ca2+ transients before substantial plaque formation. Neuropixels recordings revealed that these abnormal transients were associated with reduced spiking and impaired visual tuning of parvalbumin (PV)-positive fast-spiking interneurons (FSIs) in layers 5/6, whereas PV-FSIs in superficial layers remained unaffected. These dysfunctions occurred alongside a deep-layer-specific reduction in neuronal pentraxin 2 (NPTX2) within excitatory neurons, decreased GluA4 in PV-FSIs, and fewer excitatory synapses onto PV-FSIs. Notably, NPTX2 overexpression increased excitatory input onto layers 5/6 PV-FSIs and rectified their spiking activity. Thus, our findings reveal an early selective impairment of deep cortical layers 5/6 in AD models and identify deep-layer PV-FSIs as therapeutic targets.
Cost-effectiveness of screening with transcriptional signatures for incipient TB among U.S. migrants
Authors: Yuli Lily Hsieh, C Robert Horsburgh, Ted Cohen, Jeffrey W Miller, Joshua A Salomon, Nicolas A Menzies
Journal: PLoS Medicine (2025)

Background Host-response-based transcriptional signatures (HrTSs) have been developed to identify “incipient tuberculosis (TB)”. No study has reported the cost-effectiveness of HrTS for post-arrival migrant screening programs in low-incidence countries. The aim of this study was to assess the potential health impact and cost-effectiveness of HrTS for post-arrival TB infection screening among new migrants in the United States. Methods and findings We used a discrete-event simulation model to compare four strategies: (1) no screening for TB infection or incipient TB; (2) ‘IGRA-only’, screen all with interferon-gamma release assay (IGRA), provide TB preventive treatment for IGRA-positives; (3) ‘IGRA-HrTS’, screen all with IGRA followed by HrTS for IGRA-positives, provide incipient TB treatment for individuals testing positive with both tests; and (4) ‘HrTS-only’, screen all with HrTS, provide incipient TB treatment for HrTS-positives. We assessed outcomes over the lifetime of migrants entering the United Stataes (U.S.) in 2019, assuming HrTS met WHO Target Product Profile (TPP) optimal criteria. We conducted sensitivity analyses to evaluate the robustness of results. Our findings show that at a willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY) gained, the IGRA-only strategy was the optimal strategy under both healthcare sector and societal perspectives, with an incremental cost-effectiveness ratio (ICER) of $104,138 and $143,103 per QALY gained, respectively. At a willingness-to-pay of $100,000 per QALY gained the IGRA-HrTS strategy appeared optimal. When the cohort was stratified by TB incidence in the country of origin, the IGRA-only strategy was optimal for country-of-origin incidence ≥100 per 100,000, and the no-screening strategy was optimal for country-of-origin incidence &lt;10 per 100,000. The IGRA-HrTS strategy was potentially cost-effective with country-of-origin incidence of 10–100 per 100,000, though this result had substantial uncertainty. Results were sensitive to time trends in TB progression risk after U.S. entry. Conclusions An HrTS test meeting WHO TPP optimal criteria would be potentially cost-effective for post-arrival screening among a subset of U.S. migrants, but this result was sensitive to multiple factors.
Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up
Authors: F d'Amore, M Federico, L de Leval, F Ellin, O Hermine, W S Kim, F Lemonnier, J S P Vermaat, G Wulf, C Buske, M Dreyling, M Jerkeman
Journal: Annals of Oncology (2025)
Differentiating Psoriasis From Eczema With Interleukin-36 Gamma Immunohistochemistry on Skin Biopsy Specimens: A Retrospective, Single-Center Validation and Cohort Study
Authors: Adilson DaCosta, H Giang Nguyen, Tung S Tran, Trang M Nguyen, Marian T McEvoy, David A Wetter, Julie A Vrana, Austin Todd, Anja C Roden, Julia S Lehman
Journal: Journal of the American Academy of Dermatology (2025)
Engineered Neuromedin U Promotes Type 2 Innate Immunity and Renoprotection in Acute Kidney Injury
Authors: Sara Trindade-Correia, Vasco Correia, Filipe Delgado, Marta Baptista, Inês Amendoeira Cabral, Tânia Carvalho, Luana Macedo, Margarida Nunes, Pedro Z Andrade, Filipa Cardoso, Julie Chesné, David F Braga Malta, Covadonga Pañeda, Henrique Veiga-Fernandes, Vânia Cardoso
Journal: Journal of the American Society of Nephrology (2025)

Background: Acute kidney injury (AKI) is a severe condition leading to the sudden loss of kidney function. Activation of type 2 innate lymphoid cells (ILC2s) by neuromedin U (NMU) is highly selective and key in controlling mucosal tissue repair and homeostasis. Renal ILC2s are associated with renoprotective effects in AKI. Here, we explored the therapeutic potential of an engineered NMU analogue (LIMM102) in a preclinical model of renal ischemia-reperfusion injury (IRI)-induced AKI. Methods: LIMM102 was administered prophylactically to wild-type (WT) mice subjected to IRI-induced AKI and to sham-operated controls. Survival, glomerular filtration rate (GFR), kidney function biomarkers, histopathological analysis, and immune cell infiltration were assessed to determine LIMM102 treatment efficacy. Moreover, to interrogate the molecular selectivity of LIMM102, NMUR1-deficient mice ( Nmur1 −/− ) were used to formally test the need of NMUR1 signalling for the beneficial effects of LIMM102. Results: LIMM102-treated IRI animals presented reduced mortality rates when compared to their untreated IRI counterparts. Notably, LIMM102-treated animals displayed higher GFR, lower levels of kidney function biomarkers, and lower severity of kidney lesions, which associated with renal ILC2-activated phenotypes. Importantly, LIMM102 therapeutic effects relied entirely on NMUR1 signalling, as LIMM102 administration produced no beneficial effect on AKI outcome in Nmur1 deficient animals. Conclusions: LIMM102 exerted its renal therapeutic action by improving kidney function in IRI-induced AKI via NMUR1, which was associated with the presence of activated ILC2s in the kidney.
Internet-Delivered Treatment for Stress-Related Disorders: A Randomized Controlled Superiority Trial of Cognitive Behavioral Therapy versus General Health Promotion
Authors: Victoria Sennerstam, Ludwig Franke Föyen, Evelina Kontio, Frank Svärdman, Mats Lekander, Elin Lindsäter, Erik Hedman-Lagerlöf
Journal: Psychotherapy and Psychosomatics (2025)

Background: Stress-related disorders such as adjustment disorder (AD) and exhaustion disorder (ED) are associated with substantial suffering and high societal costs. Cognitive behavioral therapy (CBT) is a promising treatment for symptom reduction but has not been rigorously compared with other active treatments. This study aimed to investigate the efficacy of CBT compared to an active control treatment (General Health Promotion; GHP) treatment for individuals diagnosed with AD or ED. Methods: A total of 300 adults diagnosed with AD or ED were randomly assigned to a 12-week CBT (n=151) or GHP (n=149), both delivered as therapist-supported online treatments. Primary outcome was post-treatment scores on the 10-item Perceived Stress Scale. Secondary outcomes included several mental health symptom domains and functional impairment. All outcomes were assessed at baseline, post-treatment, and at 1-year follow-up. The trial was pre-registered on Clinicaltrials.gov (NCT04797273). Results: The CBT intervention was not superior to GHP in reducing symptoms of perceived stress and secondary symptoms. Both treatments generated large within-group effect sizes pre- to post-treatment (Cohen’s d= 1.19 and 1.06, respectively) and results were maintained to the 1-year follow-up. Diagnostic group moderated the treatment effect pre- to post-treatment and indicated that CBT was superior to GHP for individuals diagnosed with AD but not for those diagnosed with ED. Conclusions: Common factors likely play an important role in symptom reduction for individuals with stress-related disorders. A refined understanding of the conceptualization of stress-related disorders and which specific mechanisms to target in the respective patient groups is needed to improve treatment outcomes.
Controlled Release of Ionic Carrier Hydrogels for Sequential Immunomodulation to Facilitate Stage-specific Treatment of Infectious Wound
Authors: Zhuocheng Lyu, Yuezhou Wu, Fei Hu, Xu Zheng, Dajun Ma, Zhenjiang Xu, Yurun Ding, Xuesong Liu, Shicheng Huo
Journal: Biomaterials (2025)
Deprescribing in Community-Dwelling Older Adults
Authors: Amy M. Linsky, Aneesa Motala, Marika Booth, Emily Lawson, Paul G. Shekelle
Journal: JAMA Network Open (2025)

Importance Deprescribing has the potential to improve patient safety and quality of care by reducing polypharmacy and potentially inappropriate medications (PIMs), which in turn may reduce adverse drug events. Questions remain about the effectiveness of deprescribing interventions in outpatient settings. Objective To determine the association of deprescribing interventions with reducing medication count and PIMs in community-dwelling older adults. Data Sources Included studies were English-language human studies in PubMed and the Cochrane Library published from January 2019 to July 26, 2024, and results were supplemented with reference-mining and expert consultation. Study Selection Studies were eligible if they were solely or primarily about deprescribing, focused on community-dwelling adults, were multisite, used a randomized trial design, and reported on the primary or secondary outcome. Data Extraction and Synthesis Two authors extracted study design, intervention characteristics, population characteristics, and follow-up. Outcomes were extracted by the statistician and checked by a second author. Meta-analyses were conducted using random effects with the Hartung-Knapp-Sidik-Jonkman method. The study was reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria. Main Outcomes and Measures The primary outcome was the number of PIMs or total medications, and the secondary outcome was proportion of persons prescribed at least 1 PIM. Results Two authors independently screened 1586 titles from PubMed and Cochrane and 33 from other sources; 321 abstracts and 133 full-text studies were further reviewed, and disagreements were reconciled through discussion, resulting in 17 studies in 18 publications. A total of 8 studies of interventions targeting multiple medications were identified for primary outcome analysis; the random-effects pooled analysis found a mean difference of −0.14 (95% CI, −0.27 to −0.01) medications prescribed. A total of 6 studies of interventions targeting multiple medications were identified for secondary outcome analysis; the random effects pooled analysis found no significant reduction in the proportion of persons prescribed at least 1 PIM (odds ratio, 0.92 [95% CI, 0.74 to 1.14]). Conclusions and Relevance This systematic review and meta-analysis found moderate-certainty evidence that deprescribing interventions were associated with reduced PIM and medication counts in community-dwelling older adults. While the individual-level association was very small, on an aggregated population level, the outcomes may be large, given the high prevalence of polypharmacy and PIMs in community-dwelling older adults.